Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, has shown substantial efficacy in relapsed CHL, especially in older or frail patients unable to tolerate ABVD chemotherapy [8]. This evidence concerns the gene TNFRSF8 and classic Hodgkin lymphoma.